Takeda's FRUZAQLA Approved For Reimbursement By BC Cancer For Metastatic Colorectal Cancer

Benzinga · 21h ago

Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.[1]  This treatment is available to patients under certain criteria.